As of 2026-01-06, the EV/EBITDA ratio of Urogen Pharma Ltd (URGN) is -6.95. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. URGN's latest enterprise value is 1,072.70 mil USD. URGN's TTM EBITDA according to its financial statements is -154.36 mil USD. Dividing these 2 quantities gives us the above URGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.8x - 10.0x | 9.8x |
| Forward P/E multiples | 9.1x - 12.0x | 11.4x |
| Fair Price | (30.86) - (33.70) | (35.74) |
| Upside | -239.5% - -252.3% | -261.5% |
| Date | EV/EBITDA |
| 2026-01-02 | -7.13 |
| 2025-12-31 | -7.34 |
| 2025-12-30 | -7.26 |
| 2025-12-29 | -7.31 |
| 2025-12-26 | -7.22 |
| 2025-12-24 | -7.44 |
| 2025-12-23 | -7.33 |
| 2025-12-22 | -7.39 |
| 2025-12-19 | -7.15 |
| 2025-12-18 | -6.82 |
| 2025-12-17 | -7.10 |
| 2025-12-16 | -7.36 |
| 2025-12-15 | -7.17 |
| 2025-12-12 | -6.85 |
| 2025-12-11 | -7.02 |
| 2025-12-10 | -6.97 |
| 2025-12-09 | -7.12 |
| 2025-12-08 | -7.24 |
| 2025-12-05 | -7.21 |
| 2025-12-04 | -7.60 |
| 2025-12-03 | -7.62 |
| 2025-12-02 | -7.63 |
| 2025-12-01 | -8.87 |
| 2025-11-28 | -8.97 |
| 2025-11-26 | -9.16 |
| 2025-11-25 | -8.64 |
| 2025-11-24 | -8.40 |
| 2025-11-21 | -8.08 |
| 2025-11-20 | -7.77 |
| 2025-11-19 | -7.90 |
| 2025-11-18 | -7.38 |
| 2025-11-17 | -7.43 |
| 2025-11-14 | -7.44 |
| 2025-11-13 | -7.49 |
| 2025-11-12 | -7.86 |
| 2025-11-11 | -7.40 |
| 2025-11-10 | -7.25 |
| 2025-11-07 | -7.29 |
| 2025-11-06 | -7.38 |
| 2025-11-05 | -6.09 |
| 2025-11-04 | -6.25 |
| 2025-11-03 | -6.49 |
| 2025-10-31 | -6.45 |
| 2025-10-30 | -6.26 |
| 2025-10-29 | -6.24 |
| 2025-10-28 | -6.36 |
| 2025-10-27 | -6.56 |
| 2025-10-24 | -5.99 |
| 2025-10-23 | -5.49 |
| 2025-10-22 | -5.59 |